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Testing regenerative properties of 3D bioprinted cardiac patches in vivo using murine
models of heart failure via permanent left anterior descending (LAD) ligation is a
challenging procedure and has a high mortality rate due to its nature. We developed
a method to consistently transplant bioprinted patches of cells and hydrogels onto
the epicardium of an infarcted mouse heart to test their regenerative properties in
a robust and feasible way. First, a deeply anesthetized mouse is carefully intubated
and ventilated. Following left lateral thoracotomy (surgical opening of the chest), the
exposed LAD is permanently ligated and the bioprinted patch transplanted onto the
epicardium. The mouse quickly recovers from the procedure after chest closure. The
advantages of this robust and quick approach include a predicted 28-day mortality rate
of up to 30% (lower than the 44% reported by other studies using a similar model of
permanent LAD ligation in mice). Moreover, the approach described in this protocol
is versatile and could be adapted to test bioprinted patches using different cell types
or hydrogels where high numbers of animals are needed to optimally power studies.
Overall, we present this as an advantageous approach which may change preclinical
testing in future studies for the field of cardiac regeneration and tissue engineering.
Introduction
A heart transplant is the gold standard treatment for patients
with end-stage heart failure but there is a shortage of
donor organs. It requires immune system suppression to
prevent graft rejection and the one-year mortality rate is
15% worldwide1 . Therefore, there is a longstanding incentive
to regenerate the myocardium in preclinical animal models
with a view to translating to human trials2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 .
Recent advances in 3D bioprinting of stem cells or stem cell-
derived cardiac cells have gained attention as a promising
approach to regenerate the myocardium2 , 3 , 9 , 10 , 11 , 12 .
The first human safety trials applying patches to regenerate
the heart have been reported, with autologous bone
marrow mononuclear cells suspended in collagen or
embryonic stem cell-derived cardiac progenitor cells in fibrin,
transplanted to the epicardium7 , 8 , 13 . However, for a more
precise, scalable, automatable and reproducible method, 3D
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bioprinting of optimized hydrogel patches to be applied to the
epicardial surface of the heart is a promising approach to
regenerate the myocardium for patients who would otherwise
need a heart transplant2 , 10 , 11 , 12 .
Before translation to human trials can occur, preclinical
animal studies are needed. Preclinical in vivo models
pursuing regeneration of the myocardium have been reported
in pigs5 , sheep14 , rats6  and mice4 . A common model of
myocardial infarction (MI) in mice uses permanent ligation
of the left anterior descending (LAD) coronary artery15 , 16 .
Among the different strains of mice used, permanent LAD
ligation in C57BL6 mice has an acceptable survival rate
and typically presents consistent remodeling and cardiac
changes after MI16 . In rodent models, several approaches
have been described where cardiac tissue has been applied
to the heart in pursuit of effective regeneration of damaged
myocardium4 , 6 , 17 . While large animals still represent a
more clinically relevant model to test cardiac regenerative
properties5 , 14 , the versatility and feasibility of the mouse
model lends itself to this fast-moving area of study. This
may avoid some of the pitfalls typical of large animal
studies, including (but not limited to): 1) high animal mortality
(unless diagonal coronary arteries are ligated leading to
unpredictable segmental infarcts14 , or the distal end of
the LAD is occluded followed by reperfusion instead of
permanent ligation5 ); 2) ethical issues with the relatively
increased harm caused by large animal protocols compared
to mice18 ; 3) increased cost and/or feasibility issues, for
instance the relative unavailability of large animal equipment
such as MRI scanners14 . It is also important to consider
that given the extensive duration and commitment typical
of large animal studies, they have the potential to become
outdated before they are finished, especially with the
rapid developments typical of this field. For instance, it is
only recently that the critical role played by inflammatory
cells and mediators in regulating cardiac regeneration has
emerged19 , 20 . Furthermore, the critical role of preclinical
studies, such as small animal models, has been highlighted
by a Lancet Commission as an essential step to gain robust
knowledge before moving to human trials21 .
To facilitate progress in understanding mechanisms and
optimizing conditions for patch-based cardiac regeneration
approaches in vivo, we present a novel approach describing
a ‘scoop and drape’ method to apply a 3D bioprinted alginate/
gelatine hydrogel patch to the surface of infarcted hearts
in C57BL6 mice. The aim of this approach is to provide a
versatile in vivo model to test 3D bioprinted patches that
are likely to be feasible in broad research contexts for the
rapidly-evolving field of cardiac regeneration2 . This method
could be adapted to test patches generated by non-bioprinting
methods, different hydrogels and autologous or allogenic
stem cell-derived cells within patches in vivo. However,
detailed consideration of bioprinting, hydrogels or cell types is
beyond the scope of this study which focuses on the surgical
transplantation method.
The advantages of the protocol include that the myocardial
infarction and application of a bioprinted patch are performed
in one surgical procedure that can be performed quickly,
with readily-available, cost effective laboratory tools and with
a relatively low mortality rate. It also typically allows for a
higher number of animals than large animal models in a
smaller space, which permits robust comparison of multiple
experimental groups, particularly useful for multiple group
comparison in vivo. On the other hand, this protocol has
the disadvantages that: 1) the mouse model is more distant
from human heart size, anatomy and physiology than in large
animal models and it does not directly translate into humans;
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2) the murine LAD branches proximally, with significant
variability between individual mice, which leads to infarct size
variability (a problem shared with large animal models); 3) the
patch must be applied over the whole anterior heart surface,
which is less precise than applying over a specific infarct area;
and 4) the patch is applied immediately at the time of MI (for
human use it is likely to be more clinically useful to develop a
patch for application to the chronically infarcted failing heart
months following the initial MI14 ).
Nonetheless, if chosen appropriately according to the
hypothesis being tested, this protocol can provide critical in
vivo data quickly, with high n numbers, in a way that is
consistent with the materials, budget and expertise available
in most laboratories. Compared to large animal models, it is
an in vivo model that is versatile enough to adapt to emerging
3D bioprinting technologies (for example by the relative ease
of performing pilot studies to test feasibility and safety before
moving to larger animal models). It would be well-suited for
researchers who want to generate in vivo data efficiently
and inexpensively, perhaps running multiple comparisons of
3D bioprinted patches with different bioprinting parameters,
cells or hydrogels in the patches. It would be especially
useful for testing the interactions of different mixtures of
stem cells and stem cell-derived cells with hydrogels in
vivo without excess wastage of expensive cell lineages or
other materials that might occur if using large scale patches.
Using a mouse model would also facilitate testing of patches
containing species-compatible mouse-derived cell and stem
cell lineages or human-derived cells where uniform mice
with a specific immune deficiency are desirable. Additionally,
testing in genetically modified mouse strains could allow
researchers to isolate the effects of specific genes on
signaling pathways and in specific cell types relevant to
cardiovascular disease, which would not currently be possible
in a large animal model.
Protocol
All procedures described in this experiment were approved by
the Animal Ethics Committee at the Northern Sydney Local
Health District, NSW, Australia (project number RESP17/55).
1. Anesthesia and intubation
NOTE: Turn on and set up the stereomicroscope, the heat
pad (covered with an absorbant sheet) and ventilator system.
1. Clean gloves, the surgical area, and the tools with 70%
ethanol.
2. Weigh the mouse to calculate the dosage of anesthesia
injected by the intraperitoneal route (ketamine 40 mg/
kg, xylazine 5 mg/kg, atropine 0.15 mg/kg) and give the
injection.
3. Once the mouse reaches a deep plane of anesthesia,
shave the ventral left side of the thorax with a trimmer.
4. Place the mouse in a chamber containing 2% isoflurane
(ensuring adequate extraction ventilation in the room).
 
NOTE: The relatively low dose of ketamine/xylazine
injection together with 2% isoflurane inhalation reduces
the risk of mouse death while allowing optimal intubation
without waking the mouse up.
5. Place the mouse supine and restrain it from its upper
incisor teeth with a 3.0 suture taped to the bench, as
shown in the video. Confirm sedation by performing a
toe pinch. Position a high-intensity illuminator above the
mouse neck so that the oropharynx can be visualized.
 
NOTE: Alternatively, the mouse can be placed on the
stand from the intubation kit (e.g., Kent Mouse Intubation
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Kit) with an elastic band secured under the top incisors to
hold the mouth open to identify the trachea.
6. Use a curved spatula to open the jaw and another pair
of spatulas/blunt forceps to lift the tongue gently out of
the way. Be sure to intubate while positioned at or slightly
below eye-level with the body of the mouse.
7. Visualize the opening and closing of the vocal cords.
When open, insert the 20 G plastic catheter supplied with
the intubation kit.
8. Carefully transfer the intubated mouse to an operating
surface equipped with a heating pad. Connect the mouse
to the ventilator (e.g., MouseVent) that automatically sets
the target volume based on mouse weight.
9. Deliver 1.5-2% isoflurane with oxygen (which is
automatically regulated by the ventilator: ensure there is
a connection from an oxygen cylinder to the automatic
ventilator at 1-2 L/min flow rate to the ventilator). Verify
the intubation by checking for bilateral chest rise. Verify
anesthesia by performing a toe pinch.
10. Apply opthalmic ointment (e.g., Puralube Vet Opthalmic
Ointment) to both eyes to prevent them from drying out.
2. Preparing the surgical field
1. Secure the intubation tube with tape at the connecting site
between the ventilator and the breathing tube/catheter.
2. Cut a longer piece of tape and secure its left front foot to
the operating surface in a slightly elevated position. Also
tape down the other extremities.
3. Clean the chest with sterile 70% isopropanol and
povidone iodine solution, cleaning in a circular motion
moving from center to periphery.
4. Verify anesthesia once more with a toe pinch.
5. Administer 0.08 mg/kg Temvet (buprenorphine) in 0.1 mL
of 0.9% saline via subcutaneous injection.
3. Left lateral thoracotomy
1. Use fine-tip forceps to gently lift the skin at a point
approximately 5 mm to the left of the prominent xiphoid
cartilage. Use surgical scissors to create a superomedial
incision in the skin from this point upwards and towards
the midline, to the level of the manubrium.
2. Use curved forceps to gently separate the skin and
muscle layers. Open the muscle layer, following the skin
incision.
3. Identify and make an incision in the third intercostal
space, following the natural angle of the ribcage.
4. Use a retractor to gently spread apart the 3rd and 4th ribs.
5. Gently remove the thin pericardium with forceps.
6. If the LAD is not visualized, gently push the left auricle
(see Supplementary Figure 1) upwards and locate the
coronary arteries underneath.
4. Left anterior descending (LAD) permanent
coronary artery ligation
1. Cut a ~3 mm long 3-0 silk suture and put this reinforcing
3-0 silk suture piece on top of the LAD in the same
direction as the LAD (as shown in the video at time point
02:12 – 02:20).
2. Identify the LAD and pass a 7-0 silk suture under the LAD.
If the LAD is not clearly visualized, insert the needle 1 mm
inferior and medial to the inferiormost point reached by
the tip of the left auricle during dynamic movement of the
heart.
 
NOTE: This structure is a lighter color red to the
ventricular chambers of the heart but darker than the
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adjacent lung and is best visualized in the video at time
point 01:54 – 01:55 where it is visible just inferior to the
superior arm of the retractor, superior to the left lung (see
Supplementary Figure 1 for annotated video still image).
3. Complete two throws with the 7-0 silk suture and close it
tightly passing on top of the supportive 3-0 silk suture to
secure the LAD. If the ligation is successful, the anterior
ventricular area distal from the ligature will blanch.
4. Complete the knot with a third throw in the opposite
direction to secure it, ensuring no upward traction force
is transmitted to the suture. Additional throws are not
required to reduce the risk of damage to the myocardium
or LAD by suture cutting through.
5. Transplantation of the bioprinted patch onto the
epicardium
1. Carefully move the bioprinted patch from a six well plate
to the infarct area by using the sterile inside surface of an
opened surgical scalpel packet.
2. Carefully position the bioprinted patch onto the anterior
epicardial surface, where it should cover the whole
surface and drape over the inferior and lateral edges,
covering the left ventricle and the infarct zone (blanched
area).
3. Gently close and remove the retractor without directing
sharp edges towards the heart.
4. Use 6-0 prolene sutures in a simple interrupted pattern to
close the ribcage and the muscle layers.
5. With the Sigh Breath function while closing the chest
with the 6-0 prolene sutures, inflate the lungs to remove
excess air in the pleural cavity, which would otherwise
become trapped in the chest cavity and result in a
pneumothorax.
6. Ensure that the chest is tightly sealed.
7. Decrease the isoflurane to 1.0%. Close the skin with 6-0
prolene sutures in a simple interrupted pattern. Turn the
isoflurane vaporizer off.
6. Mouse recovery
1. Topically apply 2 mg/mL bupivacaine in 0.9% saline to
the incision. Administer also: i) Antisedan (atipamezole) 1
mg/kg; ii) Lasix (furosemide) 8 mg/kg; iii) 600 µL of 0.9%
saline solution via a subcutaneous injection.
 
NOTE: Antisedan is to reverse the anesthetic more
rapidly; furosemide is to offload excess fluid due
to cardiac output compromise and additional fluid
administered with drug injections.
2. Monitor the mouse and wait until independent breathing is
observed to remove the mouse from the intubation tube.
3. When the mouse demonstrates an adequate bilateral
breathing rate and depth and responds to a toe pinch,
place the mouse in a clean recovery cage placed on a
heat pad.
4. Provide the mouse with moist food (moistened for
chewability), a water bottle and nutrient/hydrating
gel. Monitor for an exaggerated breathing effort,
excessive bleeding, or other potentially life-threatening
complications.
5. For the next three days, administer 0.08 mg/kg
Temvet (buprenorphine) in 0.1 mL of 0.9% saline via
subcutaneous or intraperitoneal injection, twice daily,
then once daily up to the fifth day following the procedure.
6. House mice in pairs separated by cage dividers to prevent
isolation whilst preventing fighting behaviors. Monitor
mice at least daily until the end of the experiments (28
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days) with close attention to their wellbeing and increased
frequency of monitoring if there are any concerns.
Representative Results
At transplantation, the viscosity of the patch at room
temperature (without additional crosslinker being applied)
allowed it to ‘drape’ over the contours of the heart (Figure
1) and move dynamically with the cardiac cycle. After the
surgery, we left the patches for 28 days in vivo as studies
have found this to be a suitable time period allowing for patch
effects on host cardiac function3 , 4  (although it has been
reported that full functional effects may not be seen until
three months after transplantation)22 . The photograph of a
patch shown in situ on a mouse heart in Figure 1 was taken
immediately after application, showing the ability of the patch
to drape over the heart at transplantation. This representative
result shows that the hydrogel allows for the patch to mold
to the contours of the heart and where excessive tension
occurred the hydrogel was able to split as shown by the bare
(hydrogel-free) triangular area in Figure 1 (indicated by a
black star in the image). Survival data (Kaplan-Meier survival
curves) are shown in Figure 2 compared to mice undergoing
a sham procedure (passage of a needle and suture under the
LAD without ligation followed by closure of the mouse chest).
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Figure 1: A bioprinted cardiac patch applied onto the epicardium of a C57BL6 mouse heart. A 10 mm x 10 mm x 0.4
mm bioprinted patch (immediately after transplantation) containing hydrogel (alginate 4% (w/v)/gelatine 8% (w/v) in media)
is shown draped over the infarcted area and adhering to the epicardial surface (white arrowheads and dotted lines = border
of the patch). The patch viscosity allows it to mold to the contours of the heart and where excessive tension occurred at the
superior aspect the patch has split to make a triangular bare area not covered by hydrogel (black star). Please click here to
view a larger version of this figure.
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Figure 2: Kaplan-Meier survival analysis through 28 days post-MI. Nine mice in the procedural group died (n=38) to give
an overall mortality rate of 24%. Please click here to view a larger version of this figure.
Supplementary Figure 1: Video still image (video time
point 01:54 – 01:55) showing the left auricle (left atrial
appendage). The arrow points to the inferomedial tip of the
left auricle which is visible as a triangular structure at the
superior left edge of the heart. In case the LAD is not clearly
visualized, the tip of the left auricle can be used as a landmark
for needle entry to pass a suture under the LAD. The entry
point is 1 mm inferior and medial to the inferiormost point
the tip of the left auricle reaches during dynamic movements
of the heart (black arrow shows inferomedial tip of the left
auricle). Please click here to download this figure.
Discussion
The method facilitates the operator to efficiently transplant
a bioprinted patch by applying it to the epicardial surface of
an infarcted mouse heart following permanent LAD ligation.
In this feasibility-focused method, we are able to perform
this procedure on eight mice per working day (including
preparation of the room before and afterwards). A bioprinting
run producing eight 1 cm2  patches in wells of six-well plates
takes 2-3 hours (including preparation time before and after).
We used the sterile inside of a surgical scalpel packet as the
scoop for our patch, which is readily accessible and generally
adds minimal cost, utilizing the natural adhesive properties of
the alginate/gelatine hydrogel patch to drape the patch across
the anterior infarcted surface of the heart. In our experience,
the protocol for LAD ligation in mice is operator dependent
and a lower mortality rate at 28 days can be achieved with
experienced operators specialized in one model. Van den
Borne et al.16  reported that C57BL6 mice present a 44%
mortality following permanent LAD ligation at 28 days without
the application of a patch, which is higher than the upper limit
of 30% that we observed with the method.
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The intubation step is critical and in-and-of-itself can be a
source of mortality for mice unless performed by a skilled
operator. It is made difficult due to the tiny size of the trachea,
which is why magnifying glasses are worn by the operator
for this step. We use injected ketamine/xylazine as well as
inhaled isofluorane for induction of anesthetic so that the
mouse is deeply anesthetized at relatively low doses of each
drug. Therefore, there is no risk for the mouse to wake up
during this intubation step but the high mortality associated
with high single-drug doses is avoided. Atropine was also
given to counteract side effects such as bradycardia and
hypersalivation. The use of a spotlight applied to the throat
externally lights up the trachea internally so it is more visible
and the vocal cords must be visualized opening and closing
with the mouse’s respiratory rate (usually ~120 breaths per
minute). It is critical to position the mouse perfectly (which
is why a hard surface is preferred rather than a warming
mat underneath the mouse for this step) with the two incisor
teeth held by a looped thread and the tongue retracted
extremely gently with blunt forceps/pair of spatulas to open
the mouth and visualize the trachea. Once the intubation is
completed, the operator must be careful not to dislodge the
tube in the transfer from the intubation area to the operating
bed (which does have a heat mat underneath it to prevent
hypothermia). When connecting the breathing tube to the
ventilator apparatus, it is critical to stabilize the tube with one
hand and connect the ventilator circuit with the other, so that
there is minimal movement of the breathing tube such as
pushing it more deeply into the trachea when connecting the
ventilator segment of the tubing.
In this study, we used alginate 4% (w/v)/gelatine 8% (w/
v) in Dulbecco’s Modified Eagle Medium (DMEM). Alginate/
gelatine hydrogels are known for their biocompatibility, low
cost and biomechanical properties making them useful for
3D tissue engineering strategies23 . These hydrogels can
be crosslinked by mild gelation by adding calcium ions,
which allows for viscosity to be altered. After bioprinting,
we applied calcium chloride (CaCl2) 2% (w/v) in phosphate-
buffered saline (PBS) onto patches and then cultured them
in DMEM in six well plates for 7-14 days before transplanting
them. This was the optimal window after patches containing
cardiac cells started to beat in culture but before patches
started to disintegrate. Whilst CaCl2 could be added regularly
throughout the post-bioprinting phase to reduce patch
disintegration, we found that the intrinsic viscosity of the
hydrogel was sufficient for patches to maintain their structure
up to transplantation with only one initial dose of CaCl2.
The method allowed for successful transplantation without
sutures (which may damage the heart) or glue (which
may block the interface between the patch and the
heart). Future studies may confirm the hypothesis that
sutureless and glueless transplantation does not negatively
impact engraftment in mice as it is critical that the
patch does not slip off the heart or interfere with the
lungs. Other studies assessing engraftment of patches in
permanent LAD ligation models with patch-based repair3
have measured engrafted area (mm2 ) remaining with
time24 , the grafted patch thickness (μm) remining with
time25 , quantification of transplanted cells by polymerase
chain reaction (PCR)26  or bioluminescence photon emission
flux of labelled live donor cells (a measure of photons
emitted per second which can quantify labelled grafted cells
surviving in living animals over time)27 . Future studies may
use these methods to further evaluate whether sutureless
and glueless transplantation affects patch engraftment (as
well as structural and functional effects on the host
myocardium). Nonetheless, macroscopically after 28 days in
vivo in our immunocompetent mice, the anterior mediastinum
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presented variable fibrinous material and adhesions. The
mechanism of patch-based cardiac regeneration may be from
stimulation of host macrophage inflammatory responses19
or secreted immunological factors20  rather than numerical
cell replenishment. If inflammation plays a positive role, the
presence of foreign hydrogel material may be beneficial.
Alternatively, to reduce the presence of foreign material it
may be beneficial if the hydrogel component disintegrates
over time. In fact, some approaches use biomaterials
which support cells initially and then disintegrate, leaving
only tissue28 , 29 . Future studies to fully analyze patch
engraftment and better understand the mechanisms behind
patch-based cardiac regeneration may lead to optimized
experimental designs before translation to human trials2 .
Overall, this protocol is likely to be widely feasible and also
suited to testing multiple groups of 3D bioprinted patches,
for instance with different cellular contents. Future directions
for this method include the bioprinting of patches containing
advanced hydrogels not previously tested in vivo or testing
the effects of different autologous or allogenic stem cell-
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